

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Dudley <i>et al.</i>	Customer No.	: 11030
Serial No.	: 10/829,618	Confirmation No.	: 7286
Filed	: 4/20/2004	Group Art Unit	: 1627
Examiner	: Jean-Louis, Samira JM		
For	: ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION		

SUPPLEMENTAL STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

FILED VIA EFS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

In accordance with 37 C.F.R. 1.2 and M.P.E.P. Section 713.04, Applicants respectfully submit this Supplemental Statement of the Substance of the Interview in reply to the Interview Summary mailed on December 28, 2010, for the patent application referenced above.

Applicants acknowledge with appreciation the courtesy extended by Examiners Jean-Louis, McMillian, and Pihonak and Supervisory Patent Examiner Padmanabhan during the in person interview with the undersigned on December 17, 2010. Applicants have received and reviewed the Interview Summary mailed by the Examiner on December 28, 2010, and provide the following statements to supplement and clarify the summary provided by the Examiners.

As evident from the Interview Summary, the Information Disclosure Statements (IDSs) filed by the Applicants were discussed during the interview. Applicants noted during the interview that a first supplemental IDS was filed on November 12, 2010, which included a listing of related and co-pending U.S. patent applications and substantive communications therein, as well as search reports issued and oppositions filed in related or co-pending foreign patent applications. Also submitted in the first supplemental IDS were the patents and/or publications relied upon and/or references cited in a Petition for Accelerated Examination during prosecution of the related pending U.S. patent applications or issued U.S. patents as identified. Applicants further noted a second supplemental IDS was filed on November 12, 2010, which included additional patent and non-patent literature references.


For the convenience of the Examiners, Applicants also summarized during the interview the additional non-patent materials that would be submitted by separate IDS. Particularly, and to clarify the statement in the Interview Summary dated December 28, 2010, Applicants explained that litigation, regulatory and clinical documents, among other things, would be submitted by separate IDS in accordance with U.S. disclosure requirements. Applicants indicated that similar IDSs would be submitted in related pending patent applications. Applicants note that, since the date of the in-person interview, two additional IDSs have been filed with the U.S. Patent and Trademark Office for this patent application.

No exhibits were demonstrated, and no claims or prior art rejections were discussed during this interview, although a subsequent interview was held with Examiner Jean-Louis and Supervisory Patent Examiner Padmanabhan immediately afterward to discuss the merits of this patent application.

Applicants appreciate in advance the assistance of the Examiners, and look forward to the further prosecution of this and the related U.S. patent applications.

Respectfully submitted,

Date: January 28, 2011



Sandra Lee
Patent Office Reg. No. 51,932

Daniel Hulseberg
Patent Office Reg. No. 36,554

Baker Botts L.L.P.
CUSTOMER NO. 11030
30 Rockefeller Plaza
44th Floor
New York, NY 10012-4498
Attorney for Applicant(s)
212-408-2500